Aziz Nazha
Overview
Explore the profile of Aziz Nazha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
2166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
2.
Alhajahjeh A, Nazha A
Curr Hematol Malig Rep
. 2023 Nov;
19(1):9-17.
PMID: 37999872
Purpose Of The Review: This review aims to elucidate the transformative impact and potential of machine learning (ML) in the diagnosis, prognosis, and clinical management of myelodysplastic syndromes (MDS) and...
3.
Stahl M, Bewersdorf J, Xie Z, Della Porta M, Komrokji R, Xu M, et al.
Blood Rev
. 2023 Sep;
62:101128.
PMID: 37704469
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we...
4.
Stabellini N, Nazha A, Agrawal N, Huhn M, Shanahan J, Hamerschlak N, et al.
JCO Clin Cancer Inform
. 2023 Jul;
7:e2200143.
PMID: 37463363
Purpose: Develop a cancer-specific machine learning (ML) model that accurately predicts 30-day unplanned readmissions in patients with solid tumors. Methods: The initial cohort included patients 18 years or older diagnosed...
5.
Nazha A, Elemento O, McWeeney S, Miles M, Haferlach T
Blood Adv
. 2023 Jun;
7(16):4550-4554.
PMID: 37276509
No abstract available.
6.
Zhang T, Auer P, Dong J, Cutler C, DeZern A, Gadalla S, et al.
J Hematol Oncol
. 2023 Apr;
16(1):37.
PMID: 37041565
Recurrent mutations in TP53, RAS pathway and JAK2 genes were shown to be highly prognostic of allogeneic hematopoietic cell transplant (alloHCT) outcomes in myelodysplastic syndromes (MDS). However, a significant proportion...
7.
Dong J, Buradagunta C, Zhang T, Spellman S, Bolon Y, DeZern A, et al.
J Hematol Oncol
. 2023 Mar;
16(1):21.
PMID: 36899395
Despite mitochondrial DNA (mtDNA) mutations are common events in cancer, their global frequency and clinical impact have not been comprehensively characterized in patients with myelodysplastic neoplasia (also known as myelodysplastic...
8.
Patnaik M, Zeidan A, Padron E, Platzbecker U, Sallman D, DeZern A, et al.
Leukemia
. 2022 Nov;
36(12):2934-2938.
PMID: 36335264
No abstract available.
9.
Zeidan A, Bewersdorf J, Buckstein R, Sekeres M, Steensma D, Platzbecker U, et al.
Leukemia
. 2022 Oct;
36(12):2939-2946.
PMID: 36266326
No abstract available.
10.
Stahl M, Abdel-Wahab O, Wei A, Savona M, Xu M, Xie Z, et al.
Blood Adv
. 2022 Oct;
7(12):2709-2714.
PMID: 36260702
No abstract available.